Yduqs management has called an extraordinary general meeting for November 25, 2026, to put the definitive terms of the Afya Limited merger to a shareholder vote. The meeting formally wraps up the transaction structured in September, weighing an immediate cash premium against heavy long-term equity dilution.
What Will the YDUQ3 Meeting Decide?
The meeting will vote to approve or reject the Protocol and Justification of Merger, which dissolves Afya and transfers all of its assets to the combined company. YDUQ3 shareholders will decide whether to accept a 31.0% stake in the new educational conglomerate in exchange for R$ 750 million in extraordinary dividends prior to final settlement.
The meeting was called following the educational company's board of directors' unanimous approval of the protocol on November 3, 2026. Under the timeline, if approved by shareholders on both sides, the transaction will still require antitrust clearance before becoming final, with a deadline set for March 31, 2028.
Yduqs current shareholders' slice of the combined company.
Dividend distribution prior to the deal's closing.
Budgeted cap for legal fees, advisory, and integration expenses.
The market has been pricing in the move since the company first disclosed preliminary talks. As we covered when Yduqs confirmed merger discussions with Afya, the core strategic rationale is combining Estácio's higher-education scale with the profitability of Afya's medical undergraduate ecosystem. What remained to be seen were the fine details of the corporate agreement.
Why Did the Exchange Ratio Divide the Market?
The exchange ratio awards 69% of the combined company to Afya's investors, leaving Yduqs' current unitholders with less than a third of the final business. This equity imbalance reflects market valuations: Afya operates with higher operating margins in the medical segment, whereas Yduqs carries a more leveraged balance sheet and a net margin compressed to 2.02% over the recent period.
To soften this valuation gap, the agreement secures the distribution of payouts ahead of the closing date. For minority shareholders, these distributions represent an immediate return of capital, but they cap a majority stake in a group with annual revenues exceeding R$ 5.6 billion. The projected synergies between the companies range from R$ 2.0 billion to R$ 2.2 billion in net present value, achievable within three years after integrating administrative and operational structures.
| Metric / Stage | Yduqs (Current) | Combined Group (Projected) | Portfolio Impact |
|---|---|---|---|
| Ownership Control | 100% YDUQ3 minorities | 31% minorities / 69% Afya | Significant dilution of voting power |
| Cash Distribution | R$ 0.57/share (past 12m) | R$ 750 million total | Extraordinary pre-closing payout |
| Leverage (Debt/EBITDA) | 2.62x | Gradual deleveraging | Afya's cash generation reinforces solvency |
| Operational Synergies | Zero | R$ 2.0 to R$ 2.2 billion (NPV) | Efficiency in systems and corporate costs |
Preliminary assessments from investment banks differed on how quickly these gains could be captured. Sector analysts calculated that the merger between Yduqs and Afya could unlock significant value if synergies in continuing education and medical residency were executed within the promised timeframe. However, the filed document revealed tax clauses that cast a cautious eye over those gains.
Risks Brought to Light by the Formal Document
The merger protocol introduced two uncertain conditions that require close attention from investors: scrutiny from Brazil's antitrust regulator, CADE, and compliance with the OECD's Pillar Two. The combination will create a group with heavy concentration in medical school hubs and in-person undergraduate programs, making antitrust approval a mandatory hurdle—without which the contract is terminated.
The tax risk disclosed in the protocol's annexes is unprecedented for the local shareholder base. With the succession and consolidated revenues, the group will hit the threshold for the OECD's global Pillar Two rules, which impose a minimum effective tax rate of 15% per jurisdiction. Management estimated an initial 2 to 3 percentage point increase in the tax rate starting in 2026, with a terminal rate estimated between 7% and 9% by 2033, cutting into a portion of future net income.
CADE approves without severe restrictions, R$ 2.2 billion in synergies are captured, and the R$ 750 million payout hits accounts.
Forced sale of medical campuses by CADE and Pillar Two tax pressure eating into operating margins.
This balance between scale advantages and regulatory hurdles triggered portfolio rotations across several institutional funds. During the second half of the year, as the education sector reacted to the business combination, sector multiples began to be reassessed en masse, highlighting that players focused on basic education and purely in-person instruction faced different pressures than medical conglomerates.
If you hold the stock in your portfolio, the November 25 meeting determines the investment's destination. A favorable vote seals the transition: your position in a generalist higher education network with declining profitability transforms into a 31% stake in a medical and healthcare-focused multinational, with extra dividends in hand in the short term. If you choose to sell beforehand, you avoid CADE volatility and international tax adaptation costs.
What to Monitor Ahead of the Vote
Investors need to monitor the distance-voting ballot (BVD) provided by the company through its investor relations channel, as well as statements from reference shareholders and institutional asset managers. With the stock trading around R$ 9.04—below the fair value calculated by our fundamentalist analysis at R$ 9.83—current pricing embeds a heavy dose of skepticism regarding the transaction's execution.
Key catalysts for the coming weeks include the publication of valuation reports from independent advisory banks hired by Yduqs' independent committee, preliminary statements from CADE's prosecution office regarding the case's complexity, and the record date details for the billion-real payouts. Until then, the investment thesis shifts away from Estácio's campus operations and becomes a pure corporate arbitrage and integration play.
Rico aos Poucos Verdict
The November 25, 2026 meeting is a watershed moment for the YDUQ3 stock. The terms put on paper require bitter concessions—loss of control and dilution down to 31%—but offer the only viable path to recover operational profitability against a 61.9% drop in net income. For those already positioned, approving the agreement tends to be the best path to unlocking value, provided investors accept the regulatory and tax risks that will accompany the asset through 2028.
